OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Oncolytics is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	139
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma	107
Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering	107
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy	76
Ferroptosis gene signature in cholangiocarcinoma	67
Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development	63
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	61
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	55
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo	50
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	50
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	50
SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC	49
Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma	47
Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus	46
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	45
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy	44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	43
Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq	43
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	40
A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy	39
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	38
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model	38
lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC	37
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer	37
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	37

Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA	37
miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC	37
Circular RNAs act as regulators of autophagy in cancer	36
PROTACs in gastrointestinal cancers	36
Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma	36
Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma	36
Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy	33
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma	33
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	33